News
Updated and committed to information
NEW TREATMENT FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER APPROVED
The EMA has approved a new drug for the benefit of patients with non-small cell lung cancer (NSCLC). It is amivantamab (Janssen), a new drug
MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION
The authors report the 5-year follow-up data for the SOLO1 trial. Progression-free survival (PFS) was significantly longer with olaparib compared with placebo, and durable PFS
NEW THERAPY APPROVED IN SPAIN FOR LUNG CANCER
One of the fastest growing and most aggressive tumors is small cell lung cancer (SCLC), against which there are hardly any robust biomarkers that allow
MOLECULAR DETERMINANTS OF OUTCOMES WITH PEMBROLIZUMAB VS PACLITAXEL IN PATIENTS WITH GASTROESOPHAGEAL ADENOCARCINOMA
In this exploratory analysis of KEYNOTE-061, the authors demonstrated a strong association between tissue tumor mutational burden (tTMB) and efficacy of second-line pembrolizumab in patients
ENCORAFENIB PLUS CETUXIMAB AS A NEW STANDARD OF CARE FOR PREVIOUSLY TREATED BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: UPDATED SURVIVAL RESULTS AND SUBGROUP ANALYSES FROM THE BEACON STUDY
BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators’ choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal
FDA APPROVES PEMBROLIZUMAB FOR ADVANCED OR METASTATIC ESOPHAGEAL/GASTROESOPHAGEAL JUNCTION CANCER
The United States Food and Drug Administration (FDA) has granted approval for Merck’s anti-programmed death ligand-1 (PD-L1) therapy pembrolizumab (Keytruda) to be used in combination
